Risk Factors for Cognitive Impairment in HIV-1–Infected Persons With Different Risk Behaviors | Dementia and Cognitive Impairment | JAMA Neurology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.186.91. Please contact the publisher to request reinstatement.
1.
McArthur  JCHoover  DRBacellar  H  et alfor the Multicenter AIDS Cohort Study Dementia in AIDS patients: incidence and risk factors.  Neurology.1993;43:2245-2252.Google Scholar
2.
Grant  IHeaton  RKAtkinson  JHfor the HIV Neurobehavioral Research Center Group Neurocognitive disorders in HIV-1 infection.  Curr Top Microbiol Immunol.1995;202:11-32.Google Scholar
3.
Stern  YMcDermott  MPAlbert  S  et al Factors associated with incident human immunodeficiency virus dementia.  Arch Neurol.2001;58:473-479.Google Scholar
4.
d'Arminio  MADuca  PGVago  LGrassi  MPMoroni  M Decreasing incidence of CNS AIDS-defining events associated with antiretroviral therapy.  Neurology.2000;54:1856-1859.Google Scholar
5.
Childs  EALyles  RHSelnes  OA  et al Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy.  Neurology.1999;52:607-613.Google Scholar
6.
Bouwman  FHSkolasky  RLHes  D  et al Variable progression of HIV-associated dementia.  Neurology.1998;50:1814-1820.Google Scholar
7.
Qureshi  AIHanson  DLJones  JLJanssen  RS Estimation of the temporal probability of human immunodeficiency virus (HIV) dementia after risk stratification for HIV-infected persons.  Neurology.1998;50:392-397.Google Scholar
8.
Brew  BJDunbar  NPemberton  LKaldor  J Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of β2-microglobulin and neopterin.  J Infect Dis.1996;174:294-298.Google Scholar
9.
Chiesi  AVella  SDally  LG  et aland the AIDS in Europe Study Group Epidemiology of AIDS dementia complex in Europe.  J Acquir Immune Defic Syndr Hum Retrovirol.1996;11:39-44.Google Scholar
10.
Goodwin  GMPretsell  DOChiswick  AEgan  VBrettle  RP The Edinburgh cohort of HIV-positive injecting drug users at 10 years after infection: a case-control study of the evolution of dementia.  AIDS.1996;10:431-440.Google Scholar
11.
Bacellar  HMunoz  AMiller  EN  et al Temporal trends in the incidence of HIV-1–related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992.  Neurology.1994;44:1892-1900.Google Scholar
12.
Price  RW Neurological complications of HIV infection.  Lancet.1996;348:445-452.Google Scholar
13.
Bell  JEDonaldson  YKLowrie  S  et al Influence of risk group and zidovudine therapy on the development of HIV encephalitis and cognitive impairment in AIDS patients.  AIDS.1996;10:493-499.Google Scholar
14.
Wang  FSo  YVittinghoff  E  et al Incidence proportion of and risk factors for AIDS patients diagnosed with HIV dementia, central nervous system toxoplasmosis, and cryptococcal meningitis.  J Acquir Immune Defic Syndr Hum Retrovirol.1995;8:75-82.Google Scholar
15.
Concha  MSelnes  OAVlahov  D  et al Comparison of neuropsychological performance between AIDS-free injecting drug users and homosexual men.  Neuroepidemiology.1997;16:78-85.Google Scholar
16.
Marder  KLiu  XStern  Y  et al Risk of human immunodeficiency virus type 1–re lated neurologic disease in a cohort of intravenous drug users.  Arch Neurol.1995;52:1174-1182.Google Scholar
17.
De Ronchi  DFratiglioni  LRucci  P  et al The effect of education on dementia occurrence in an Italian population with middle to high socioeconomic status.  Neurology.1998;50:1231-1238.Google Scholar
18.
Starace  FBaldassarre  CBiancolilli  V  et al Early neuropsychological impairment in HIV-seropositive intravenous drug users: evidence from the Italian Multicentre Neuropsychological HIV Study.  Acta Psychiatr Scand.1998;97:132-138.Google Scholar
19.
Stern  RASilva  SGChaisson  NEvans  DL Influence of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus–1 infection.  Arch Neurol.1996;53:148-153.Google Scholar
20.
Maj  MSatz  PJanssen  R  et al WHO Neuropsychiatric AIDS Study, cross-sectional phase II: neuropsychological and neurological findings.  Arch Gen Psychiatry.1994;51:51-61.Google Scholar
21.
Satz  PMorgenstern  HMiller  EN  et al Low education as a possible risk factor for cognitive abnormalities in HIV-1: findings from the Multicenter AIDS Cohort Study (MACS).  J Acquir Immune Defic Syndr.1993;6:503-511.Google Scholar
22.
Janssen  RSNwanyanwu  OCSelik  RMStehr-Green  JK Epidemiology of human immunodeficiency virus encephalopathy in the United States.  Neurology.1992;42:1472-1476.Google Scholar
23.
Wilkie  FLGoodkin  KEisdorfer  C  et al Mild cognitive impairment and risk of mortality in HIV-1 infection.  J Neuropsychiatry Clin Neurosci.1998;10:125-132.Google Scholar
24.
Shor-Posner  GMorgan  RWilkie  FEisdorfer  CBaum  MK Plasma cobalamin levels affect information processing speed in a longitudinal study of HIV-1 disease.  Arch Neurol.1995;52:195-198.Google Scholar
25.
Herzlich  BCSchiano  TD Reversal of apparent AIDS dementia complex following treatment with vitamin B12 J Intern Med.1993;233:495-497.Google Scholar
26.
Beach  RSMorgan  RWilkie  F  et al Plasma vitamin B12 level as a potential cofactor in studies of human immunodeficiency virus type 1–related cognitive changes.  Arch Neurol.1992;49:501-506.Google Scholar
27.
Marder  KSterh  YMalouf  R  et al Neurologic and neuropsychological manifestations of human immunodeficiency virus infection in intravenous drug users without acquired immunodeficiency syndrome: relationship to head injury.  Arch Neurol.1992;49:1169-1175.Google Scholar
28.
Poutiainen  E Cognitive deficits and emotional disorders in HIV-1 infected individuals.  Acta Psychiatr Scand.1995;92:429-435.Google Scholar
29.
Work Group on HIV/AIDS, American Psychiatric Association Practice guideline for the treatment of patients with HIV/AIDS.  Am J Psychiatry.2000;157:1-62.Google Scholar
30.
Clifford  DB Human immunodeficiency virus–associated dementia.  Arch Neurol.2000;57:321-324.Google Scholar
31.
De Ronchi  DFaranca  IForti  P  et al Development of acute psychotic disorders and HIV-1 infection.  Int J Psychiatry Med.2000;30:173-183.Google Scholar
32.
Price  RWYiannoutsos  CTClifford  DB  et aland the AIDS Clinical Trial Group and Neurological AIDS Research Consortium Study Team Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy.  AIDS.1999;13:1677-1685.Google Scholar
33.
Michaels  SHClark  RKissinger  P Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.  N Engl J Med.1998;339:405-406.Google Scholar
34.
De Ronchi  DLazzari  CRucci  PCangialosi  AVolterra  V Neurocognitive effects of zidovudine and 2′,3′-dideoxyinosine during the treatment of asymptomatic and symptomatic HIV-1 seropositive patients: comparison with non-treated patients.  Hum Psychopharmacol.1996;11:415-420.Google Scholar
35.
Not Available 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.  MMWR Recomm Rep.1992;41:1-19.Google Scholar
36.
Vlahov  DGraham  NHoover  D  et al Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count.  JAMA.1998;279:35-40.Google Scholar
37.
Hamilton  M Development of a rating scale for primary depressive illness.  J Neurol Neurosurg Psychiatry.1960;23:56-62.Google Scholar
38.
Not Available Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus–type 1 (HIV-1) infection: report of a Working Group of the American Academy of Neurology AIDS Task Force.  Neurology.1991;41:778-785.Google Scholar
39.
Benton  ALHamsher  KVarney  NRSpreen  O Contributions to Neuropsychological Assessment.  New York, NY: Oxford University Press; 1983.
40.
Rey  A L'examen Clinique en Psychologie.  Paris: Presses Universitaries de France; 1964.
41.
Wechsler  D The Measurement and Appraisal of Adult Intelligence. 4th ed. Baltimore, Md: Williams & Wilkins; 1958.
42.
Miller  L Neuropsychological assessment of substance abusers: review and recommendations.  J Subst Abuse Treat.1985;2:5-17.Google Scholar
43.
Hartman  DE Neuropsychology and the neurochemical lesion: evolution, applications and extensions.  Neurotoxicology.1988;9:401-404.Google Scholar
44.
Sweeney  JAMeisel  LWalsh  VLCastrovinci  D Assessment of cognitive functioning in poly-substance abusers.  J Clin Psychol.1989;45:346-351.Google Scholar
45.
Bondi  MWDrake  AIGrant  I Verbal learning and memory in alcohol abusers and polysubstance abusers with concurrent alcohol abuse.  J Int Neuropsychol Soc.1998;4:319-328.Google Scholar
46.
Selby  MJAzrin  RL Neuropsychological functioning in drug abusers.  Drug Alcohol Depend.1998;50:39-45.Google Scholar
47.
Bale  JFJContant  CFGarg  B  et al Neurologic history and examination results and their relationship to human immunodeficiency virus type 1 serostatus in hemophilic subjects: results from the hemophilia growth and development study  Pediatrics.1993;91:736-741.Google Scholar
48.
Schmidt  MLGamerman  SSmith  HEScott  JPDiMichele  DM Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors.  Am J Hematol.1994;47:36-40.Google Scholar
49.
Katzman  R Education and the prevalence of dementia and Alzheimer's disease.  Neurology.1993;43:13-20.Google Scholar
50.
Orrell  MSahakian  B Education and dementia.  BMJ.1995;310:951-952.Google Scholar
51.
Damos  DLJohn  RSParker  ESLevine  AM Cognitive function in asymptomatic HIV infection.  Arch Neurol.1997;54:179-185.Google Scholar
52.
Palella  FJJDelaney  KMMoorman  AC  et aland the HIV Outpatient Study Investigators Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.  N Engl J Med.1998;338:853-860.Google Scholar
53.
Stout  JCEllis  RJJernigan  TL  et aland the HIV Neurobehavioral Research Center Group Progressive cerebral volume loss in human immunodeficiency virus infection: a longitudinal volumetric magnetic resonance imaging study.  Arch Neurol.1998;55:161-168.Google Scholar
54.
Chiesi  ASeeber  ACDally  LG  et al AIDS dementia complex in the Italian National AIDS Registry: temporal trends (1987-93) and differential incidence according to mode of transmission of HIV-1 infection.  J Neurol Sci.1996;144:107-113.Google Scholar
Original Contribution
May 2002

Risk Factors for Cognitive Impairment in HIV-1–Infected Persons With Different Risk Behaviors

Author Affiliations

From the Institute of Psychiatry (Drs De Ronchi, Faranca, Berardi, and Scudellari) and the Division of Infectious Diseases, Department of Clinical and Experimental Medicine (Drs Borderi and Manfredi), University of Bologna, Bologna, Italy; and the Division of Geriatric Epidemiology, NEUROTEC, Karolinska Institutet, Stockholm, Sweden (Drs De Ronchi and Fratiglioni).

Arch Neurol. 2002;59(5):812-818. doi:10.1001/archneur.59.5.812
Abstract

Context  Although it is well established that acquired immunodeficiency syndrome dementia complex mainly develops in patients with advanced human immunodeficiency virus 1 (HIV-1) infection and severe immunosuppression, other factors that might increase the risk of early neuropsychological abnormalities are controversial.

Objective  To identify risk factors for HIV-1–related cognitive impairment.

Design  Case-control study.

Setting  Division of Infectious Diseases, University of Bologna.

Participants  We studied 272 consecutive individuals: 90 HIV-1–seronegative, 88 asymptomatic HIV-1–seropositive, and 94 symptomatic HIV-1–seropositive persons.

Main Outcome Measures  Cognitive impairment was defined as poor performance on at least 2 of the 7 neuropsychological tests included in the battery. Cutoff scores for poor performance on a test were established as 2 or more SDs lower than the mean of the seronegative group in the corresponding risk behavior strata: injecting drug users, hemophiliacs, and other risk behaviors. The following risk factors were studied: age, sex, education, risk behaviors, HIV-1 stage, lymphocyte count, and antiretroviral therapy.

Results  Compared with individuals with higher levels of education, those with less than 6 years of schooling had an odds ratio (OR) of 17.2 (95% confidence interval [CI], 3.6-83.3) for cognitive impairment, independent of age, sex, disease stage, antiretroviral therapy, and risk behavior. Compared with injecting drug users, homosexual/bisexual and heterosexual participants had ORs of 9.6 (95% CI, 2.2-42.7) and 6.3 (95% CI, 2.2-18.3), respectively, for cognitive impairment. Use of antiretroviral treatment (any vs none) was associated with lower prevalence of cognitive impairment (OR, 0.1; 95% CI, 0.0-0.3). Compared with persons with high CD4+ cell counts (≥500/µL), those with low (<200/µL) and moderate (200-499/µL) CD4+ cell counts had adjusted ORs of 8.6 (95% CI, 1.0-71.0) and 6.9 (95% CI, 1.0-48.4), respectively. The presence of prominent depressive symptoms did not change the results.

Conclusions  Low educational level, low CD4+ cell count, and homosexual/bisexual and heterosexual risk behaviors are risk factors for cognitive impairment in HIV-1–seropositive persons. Antiretroviral therapy exerts a beneficial effect against cognitive impairment in symptomatic individuals. Homosexual/bisexual and heterosexual persons who survive longer are expected to be the group at highest risk for cognitive impairment. However, the protective effect of antiretroviral therapy may balance this increased risk.

×